{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:32:21Z","timestamp":1794846741737,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42176137"],"award-info":[{"award-number":["42176137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872906"],"award-info":[{"award-number":["81872906"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijbiomac.2022.09.201","type":"journal-article","created":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T17:43:51Z","timestamp":1664127831000},"page":"562-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"PA","title":["Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer"],"prefix":"10.1016","volume":"222","author":[{"given":"Zhenzhen","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishan","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CACancer J. Clin."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0015","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.2147\/OTT.S198126","article-title":"M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22\/PI3K\/AKT signaling","volume":"12","author":"Wei","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.09.201_bb0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.canlet.2016.08.004","article-title":"Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine","volume":"381","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.09.201_bb0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.drudis.2020.11.030","article-title":"Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel","volume":"26","author":"Kaemmerer","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.09.201_bb0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/med.21644","article-title":"Modulating the tumor microenvironment with new therapeutic nanoparticles: a promising paradigm for tumor treatment","volume":"40","author":"Zhang","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0040","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4049\/jimmunol.1300096","article-title":"Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas","volume":"192","author":"Hamilton","year":"2014","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.09.201_bb0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2022.09.201_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051299","article-title":"The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer","volume":"9","author":"Nowak","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.ijbiomac.2022.09.201_bb0060","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.21873\/anticanres.15253","article-title":"The impact of tumor-associated macrophages on chemoresistance via angiogenesis in colorectal cancer","volume":"41","author":"Shibutani","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2019.10.020","article-title":"TLR 7\/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages","volume":"469","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"issue":"C","key":"10.1016\/j.ijbiomac.2022.09.201_bb0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.smim.2017.09.004","article-title":"Targeting tumor associated macrophages: the new challenge for nanomedicine","volume":"34","author":"Andon","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-018-0076-7","article-title":"Myeloid-derived suppressor cells in non-neoplastic inflamed organs","volume":"38","author":"Sendo","year":"2018","journal-title":"Inflamm. Regen."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0080","first-page":"13:6","article-title":"Nanoparticle-loaded polarized-macrophages for enhanced tumor targeting and cell-chemotherapy","volume":"13","author":"Hou","year":"2020","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0085","doi-asserted-by":"crossref","first-page":"15:577","DOI":"10.1186\/s12885-015-1546-9","article-title":"M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide","volume":"15","author":"Genin","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ijbiomac.2022.09.201_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091493","article-title":"M1 macrophage-derived exosomes loaded with gemcitabine and deferasirox against chemoresistant pancreatic cancer","volume":"13","author":"Zhao","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12935-020-01233-8","article-title":"The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations","volume":"20","author":"Lin","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"4","key":"10.1016\/j.ijbiomac.2022.09.201_bb0100","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3390\/md13042327","article-title":"Fucoidan and cancer: a multifunctional molecule with anti-tumor potential","volume":"13","author":"Atashrazm","year":"2015","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/md17010032","article-title":"Fucoidan structure and activity in relation to anti-cancer mechanisms","volume":"17","author":"van Weelden","year":"2019","journal-title":"Mar. Drugs"},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.09.201_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099396","article-title":"Fucoidan can function as an adjuvant in vivo to enhance dendritic cell maturation and function and promote antigen-specific T cell immune responses","volume":"9","author":"Jin","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.09.201_bb0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/cancers12020421","article-title":"Oligo-fucoidan prevents M2 macrophage differentiation and HCT116 tumor progression","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.09.201_bb0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijbiomac.2007.10.003","article-title":"Antioxidant activity of sulfated polysaccharide fractions extracted from Laminaria japonica","volume":"42","author":"Wang","year":"2008","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.114993","article-title":"A beta-1,3\/1,6-glucan from durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator","volume":"222","author":"Su","year":"2019","journal-title":"Carbohydr. Polym."},{"issue":"15","key":"10.1016\/j.ijbiomac.2022.09.201_bb0130","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.7150\/thno.20251","article-title":"The anti-tumor effects of M1 macrophage-loaded poly (ethylene glycol) and gelatin-based hydrogels on hepatocellular carcinoma","volume":"7","author":"Guerra","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40364-017-0106-7","article-title":"Tumor-associated macrophages, potential targets for cancer treatment","volume":"5","author":"Yang","year":"2017","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2022.09.201_bb0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/intimm\/dxaa017","article-title":"The spectrum of macrophage activation by immunometabolism","volume":"32","author":"Kang","year":"2020","journal-title":"Int. Immunol."},{"issue":"6662","key":"10.1016\/j.ijbiomac.2022.09.201_bb0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ijbiomac.2022.09.201_bb0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-008-0598-y","article-title":"Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer","volume":"58","author":"Zhang","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0155","doi-asserted-by":"crossref","first-page":"35855","DOI":"10.1038\/srep35855","article-title":"Fucoidan inhibits CCL22 production through NF-kappaB pathway in M2 macrophages: a potential therapeutic strategy for cancer","volume":"6","author":"Sun","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116131","article-title":"A review on fucoidan antitumor strategies: from a biological active agent to a structural component of fucoidan-based systems","volume":"239","author":"Oliveira","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.09.201_bb0165","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/md13031084","article-title":"Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans","volume":"13","author":"Zhang","year":"2015","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0170","doi-asserted-by":"crossref","first-page":"11864","DOI":"10.1038\/s41598-017-12111-1","article-title":"Oligo-fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ijbiomac.2022.09.201_bb0175","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41565-018-0146-7","article-title":"Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy","volume":"13","author":"Chiang","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10059-010-0105-0","article-title":"Reactive oxygen species in TNF alpha-induced signaling and cell death","volume":"30","author":"Morgan","year":"2010","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0185","series-title":"Adv. Immunol","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(01)78001-7","article-title":"Toll-like receptors and innate immunity","volume":"78","author":"Akira","year":"2001"},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.09.201_bb0190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.onc.1210906","article-title":"Toll-like receptors and immune regulation: implications for cancer therapy","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.09.201_bb0195","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1088631","article-title":"Trial watch: immunostimulation with toll-like receptor agonists in cancer therapy","volume":"5","author":"Iribarren","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109636","article-title":"Sophoridine suppresses macrophage-mediated immunosuppression through TLR4\/IRF3 pathway and subsequently upregulates CD8(+) T cytotoxic function against gastric cancer","volume":"121","author":"Zhuang","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"20","key":"10.1016\/j.ijbiomac.2022.09.201_bb0205","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.09.201_bb0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.immuni.2020.04.004","article-title":"Nucleic acid sensors as therapeutic targets for human disease","volume":"53","author":"McWhirter","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.09.201_bb0215","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-017-0198-7","article-title":"Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4","volume":"8","author":"Ying","year":"2018","journal-title":"Cell Biosci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2022.09.201_bb0225","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cmet.2016.09.008","article-title":"Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis","volume":"24","author":"Wenes","year":"2016","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.ijbiomac.2022.09.201_bb0230","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1152\/ajpendo.00002.2014","article-title":"C\/EBP alpha regulates macrophage activation and systemic metabolism","volume":"306","author":"Lee","year":"2014","journal-title":"Am. J. Physiol.Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ijbiomac.2022.09.201_bb0235","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/sj.bjc.6600254","article-title":"A phase II study of active specific immunotherapy and 5-FU\/Leucovorin as adjuvant therapy for stage III colon carcinoma","volume":"86","author":"Baars","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0240","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijbiomac.2018.09.059","article-title":"Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin","volume":"122","author":"Pawar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2022.09.201_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116715","article-title":"Beta-1,6 glucan converts tumor-associated macrophages into an M1-like phenotype","volume":"247","author":"Cheng","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"9","key":"10.1016\/j.ijbiomac.2022.09.201_bb0250","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1074\/jbc.M113.508994","article-title":"Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through akt and bad phosphorylation","volume":"289","author":"Son","year":"2014","journal-title":"J. Biol. Chem."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022021389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022021389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:59:40Z","timestamp":1762235980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022021389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":50,"alternative-id":["S0141813022021389"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.201","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}